

Aligning Physician Compensation with Organizational Imperatives

Health Industry Forum

Comprehensive Health Care Reform: What will it take to get there?

April 2, 2015

Nicholas Wolter, M.D. Chief Executive Officer www.billingsclinic.com

Health Care, Education and Research

Service Area



Who We Are

An outstanding medical foundation built upon the following cornerstones:

- A multi-specialty physician group practice in which a "community of physicians" work together in a collegial manner is at the core of this model.
- The partnering of physicians, excellent business managers, professional staff, and volunteers create a team whose synergies drive our success.
- Not-for-profit, community-owned and governed.
- Mission-driven decision-making dedicated to a higher purpose in the community and the region.
- An obsessive dedication to quality and service.

Strategic Operating Plan Design Billings Clinic...

4 Perspectives

- **Patient Care**
- Clinical and Business Processes
- Learning and Support
- Growth and Development

10 Key Strategies

- **Clinical Quality and** Patient Safety
 - **Personal Service** Excellence
- **Operational Improvement**
- Innovation
- Information System Solutions
- Our People

٠

- **Organizational Culture**
- Physician Leadership
- Financial Strength and Community Stewardship
- Net Revenue Growth

13 Initiatives

- \triangleright **Clinical Quality-Processes** and Outcomes
- Patient Safety \geq
- **PSE & Patient Satisfaction** \triangleright
- **Operational Excellence** \geq
- Clinical and Health \triangleright Services Research
- People Development & \geq Wellness
- **Brand Position** \geq
- **Clinical & Business** \geq Information Systems
- Physician Leadership \geq
- **Medical Education** \geq
- **Financial Capacity** \geq
- Community Accountability \triangleright
- Net Revenue Growth \geq



Improve Performance of Appropriate Care Scores (Core Measures) to 100%

Decrease All-cause Hospital Readmissions by 20%.

Improve the patient and family experience as measured by meeting CMS benchmark HCAHPS scores and AVATAR scores

Advance the culture of safety by improving patient safety cultural assessment overall domain score to 80% agreement by December 2015.

Reduce preventable harm by 50% by December 2015 with the ultimate goal of zero preventable harm.

Reduce the observed to expected mortality ratio from 0.73 to 0.60.

Population Health Goal: Composite Score for ACO Measures (8-33) for Care Coordination, Patient Safety, Preventive Care and Disease Management at Medicare Benchmark 90thile.



Proven changes to test for improvement



GOAL ← →	PRIMARY DRIVERS <	SECONDARY DRIVERS
Decrease all-	Medication Reconciliation	100% compliance with Meds History, Admission and Discharge Meds Rec Phone call 24 hours post Discharge to reconcile Inpatient and Outpatient Pharmacist Support
cause hospital readmissions by 20% by June of 2014 using 2012	Risk Identification	Predictive modeling tools to identify at risk populations Interdisciplinary Plans of Care
as baseline performance period.		Project BOOST or similar "Hospital Syndrome" Prevention Project
All Cause 30-Day Hospital Readmission Rate Goal: 20% fewer readmissions by June 2014	Medical Home Care Navigation	24 hour phone call and 7 day appointment goals Implement readmission preventionist work list
12.00% 10.47% 10.00% 8.59% 8.00% 9 6.00% 9		Best practice patient education strategies ("Teach Back") F/U Appt made prior to Discharge
4.00% 2.00% 0.00% 2012 Baseline Performance Goal: July 1, 20	Transitions of Care	Communication standards for transitions at discharge to PCP Alignment of efforts across organization and region for nurse navigation
Observed to Expected		Discharge Summary within 5 days
Baseline 2012 Goal: July 1, 201 1.22 ≤1	4 Metrics	RA rates to PCP's and Attending Services Monthly Dashboards monthly to CMO's, Dept Chairs, Regional Partners

















to test for improvement

Proven changes





Patient Safety Dashboard

er 2013 Projektel Jan-Der Greit Desember 2013

Reality 3013 Jan Sept

2008 2009 2010 2011 2012 2013

		Atomic and Association - T					Qu	arturly lky	calender v	mer)					Vear to Date			Manth			Quarterly Trend
Indicator	Target	Mational Benchmark	QI 11	Q2 11	Q3 11	Q111	Q1.12	Q2 12	Q312	Q4.12	Q1.13	Q2.13	Q8 18	Q413	[Q113-Q413]	Aug-13	Sep-13	Oct-13	Nov-13	Dec-13	(01'08-01'13)
Number of Serious Safety Events		Not Anailable	2	4	2	1							3	1		2	0	0	1		1
Serious Safety Events Rate Overall	0.51	Not Available	0.57	0.00	0.52	4.57	0.63	0.67	0.60	0.53	0.87	0.35	0.02	6.02	NA	0.42	0.42	4.02	0.47	0.42	X
perious sarety Events Nake Overall Montality	4.4	NUL COLORA DIR	6.47	0.00	0.57	8.47	0.0	8.87	U.L.	0.54	uar	0.45	4.0	6.42	Rear to Date	4.42	0.12	142	ua/		
Mortality: Late															104112 504111						A
(Kinpatient deaths/Hinpatient discharges)	150%	Not Available 8.6	2.1%	2.1N	1.9%	1.7%	1.1%	LIN	2.3%	1.7%	2.3%	2.1%	1.4%		1.40%	1.5%	1.5%	1.4%			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Mortality: Observed to Expected	4.75	Premier Dality Aduct)	0.85	0.81	1.01	4.28	0.71	8.69	0.99	0.64	0.76	0.83	0.74		0.75	0.89	0.76	0.71			man france
Infection Related	_																				
Surgical Site Infections (SSI) - targeted procedures (e.g. cardiac, CABG, colon, hips, knoes, lami, fusion, pacemakers, hysterectomy)	•	Not Available			- 11	7	ш	- 8			1.	0	1	8	27	1	4		1	1	MM
Surgical Site Infections by Standardized Infection Ratio (SIR) *does not include pacemakers and ICDs	5851	Sill is L	1.29	6.75	1.50	1.68	1.58	0.43	0.84	0.58	0.57	0.75	0.70	0.81	0.81	8	R evailab	e quarterly (cumulative m	etric)	m
Colon Surgical Site Infections (SSI) Publically Reported		Not Analishie	1	1	3	- 1	1	1	1	1	3	0		1	+						
Hysterectory (Abdominal) Surgical Site Infections (SSI) Publically Reported		Not Assilable						D	a	2	0	1		3	4						
Hip Prosthesis Surgical Site Infections (SSI) Publically Reported		Not Available	4	i	4	2	1	1	2	- A -	- 1	8	4	- 1	•	1					
Knees Prosthesis Surgical Site Infections (SSI) Fublically Reported	0	Not Available	0	Ð	1	1	1	D	2	0	1	0	•	2	3						
Oostridium difficile infections (IP case review)	<3/ gir.	6 2.65 / per 30,000 pt. days (hereix 0.00 hereix 0.00)	11	6	9	12	10	23	5	9	4	9	10	6	29	2	- 4	1	1	4	man
Measure tracked through December 31, 2013 Costridium difficile LabID Event by Number	< 3 / gir.	# 2.65 / per 10,000 pt. days				-		_				32	17	13	48		-			_	
Costridium difficile LabiD Event by Standardized Infection Ratio (SIR)	58+1	SIR S L OPENIO						Pub	lic Repo	orting be	igan Ja	nuary 2	013. W	ill begin	tracking on Dar	hboard	Janua	y 2014.			
NITSA Transmission	1.1	Net Andebie												T	n						~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Healthcare-associated MRSA infections	<pre> e 2 / qtv. (e 8 / sear)</pre>	Not. Available	2	2	2	4	1.1	3	1	2	a	0	1	3	10	D	•	3		0	man
MRSA Bacteremia LabiD Event	Sect	518.6 L (344590)									a -	6	4	9	22						
Central-line sesociated blood stream infection (CLASSI)	5851	518 c 1 (1445N)				P	ublic Re	porting	began .	January	2011 fc	r adult :	and nee	onatal IC	t CU. Will begin tr	acking (on Das	hboard J	lanuary 2	014.	
(Adult and neupatal ICU) Contreter-associated urinary tract infection (CAUTI)	SHIL	5451						_	_		_	_	_		I begin tracking	_	-	_			
Adult ICU only Hand Hyglene: Prior to Patient Centact Unit Submitted Data	205	091340	55N	10.00	-	\$175	945	175	375	14%		55N	315	10%	21.16	175	935		95%	8.0%	And and a second second
Hand Hygiene: After Patient Contact Unit Submitted Data	255	100%	97N	90%	97N	34%	97%	MX	215	97%	975	SEN	90%	SEN	90.5	14N	96 N	34%	HIN	85%	Antonio
Hand Hygiene: After Glove Removal Unit Submitted Data	95%	(DE) 100% (DE)	97%	\$75	99%	105	97%	875	995	105	965	67%	96%	96%		8TK	06%	86%	175	655	N Juran and a start of the star
Parient Falls		(18.)													404 12 - 03 13)						~
Number of Falls with Injury (Moderate level)		Not Available	0	0	- 1	1	5	0	- 1	1	a	2		0	1	0	0	0	0	0	a das
Number of Falls with Injury (Major level)		Not Available	0	0	0	0	1	o	1.1	D	0	1.1	D	0	1		0	0		0	
Number of Psychiatric Falls with Injury (Moderate Ievel)		Net Assolution												1.0			9			1.1	And a second sec
Number of Psychiatric Falls with Injury (Mejor level)		Not Available	1											0		1	ů.				
Pressure Ulters																					
Hospital Acquired Pressure Ulters (Counterly Prevalence Stick)	51	Below NDMQI mean	1	1	1	3	1	6	1	8	2	4	1	1			1			1	A
2013 Categories of Harm			tegories of		-				-	cal: Reduce	Descent	hin Harry I				New C		08-2013		-	
187 People Harmed		141 P	copie Harr	ned		Hour Safety &	vents:	200					1.000					beervations			
 Britas tider/sers Medizasis Drait [24, 04] Medizasis Drait [24, 04]<!--</td--><td></td><td>24</td><td></td><td></td><td>= M = M = M = M</td><td>ledication Erro ad-Itary Overs agical Site Infr Instruction diff REA Infection Its with Made its with Major</td><td>es (Cate, D-#) actation actions (SSI) offic Infections parts infic Informations infic Informations</td><td>200 -</td><td>184</td><td></td><td>94</td><td>31</td><td>300</td><td></td><td>2004 608 308 808 808 808 808 808 808 808 808 8</td><td></td><td></td><td>1.14</td><td>to Patient Conta Patient Contact Store Removal</td><td></td><td></td>		24			= M = M = M = M	ledication Erro ad-Itary Overs agical Site Infr Instruction diff REA Infection Its with Made its with Major	es (Cate, D-#) actation actions (SSI) offic Infections parts infic Informations infic Informations	200 -	184		94	31	300		2004 608 308 808 808 808 808 808 808 808 808 8			1.14	to Patient Conta Patient Contact Store Removal		
i Munit Men Spry Efferentifier						NEED VIEW MARKEN									12%						



Dashboards

- Dashboard updated monthly and published on the 2nd Friday of each month.
- Meetings for Dissemination and Discussion Monthly
 - Leadership Council
 - Department Chairs
 - Hospital Practice Committee
 - Patient Safety Committee
 - Population Health Steering Committee
 - Clinic and Hospital Leadership Meetings
 - Board and Board Committee for Quality and Patient Safety



Governance Structure & Initiatives that Contribute to Population Health





Source: Advisory Board Health Care IT Suite research and analysis.



Population Health Analytics

Physician Group Agreed on the ACO Metrics as the Common Data Set For Measurement:

- Addressed Challenges in Standardization
- Provided benchmark comparisons
- Provided reliable evidence based performance measures
- Focused on high impact diseases
- Highlight gaps in care (opportunities) for improvement
- ACO Metrics aligned with Meaningful Use Clinical Quality Metrics, HEDIS Measures, NQF Metrics, PQRS Metrics



Care Coordination & Patient Safety Domain

- ACO 8 (NQF 1789): Risk Standardized All Condition Readmission
- ACO 9 (NQF 0275): Ambulatory Sensitive Conditions Admissions: COPD/ or Asthma, age 40 and up
- ACO 10 (NQF 0277): Ambulatory Sensitive Conditions Admissions: Heart Failure (HF), age 18 and up
- ACO 11: Primary Care Physicians who successfully qualify for an EHR Program Incentive Payment
- ACO 12 (NQF 0097): Medication Reconciliation following transition in care
- ACO 13 (NQF 0101): Screening for future fall risk, age 65 and up



Preventative Care Domain

- ACO 14 (NQF 0041): Influenza Immunization, age 6 mo and up
- ACO 15 (NQF 0043): Pneumococcal vaccination for patients 65 years and older
- ACO 16a/b (NQF 0421): Body Mass index Screening, age 18 and up, calculated every 6 months, with follow up plan documented
- ACO 17 a/b (NQF 0028): Tobacco Use: Screening, age 18 & Up, with Cessation Intervention Documented
- ACO 18 a/b (NQF 0418): Screening for Clinical Depression, age 12 & up, with Follow Up Plan Documented
- ACO 19 (NQF 0034): Colorectal Cancer Screening, age 50-75, iFOBT 1 year, colonoscopy 10 year
- ACO 20 (NQF 0031): Breast Cancer Screening, age 40-69, with mammogram in 24 months
- ACO 21 a/b: Screening for high blood pressure, age 18 & up, with follow up plan documented



At Risk Population Domain: Disease Management

- ACO 22 (NQF 0729): Diabetes Mellitus: HgA1c Control (<8%), age 18-75
- ACO 23 (NQF 0729): Diabetes Mellitus: LDL Control < 100, age 18-75
- ACO 24 (NQF 0729): Diabetes Mellitus: BP Control < 140/90, age 18-75
- ACO 25 (NQF 0729): Diabetes Mellitus: Tobacco Non- Use, age 18-75
- ACO 26 (NQF 0729): Diabetes Mellitus: Aspirin or Antiplatelet Rx for DM & IVD, age 18-75
- ACO 27 (NQF 0059): Diabetes Mellitus: HgA1c Poor Control (>9%), age 18-75
- ACO 28 (NQF 0018): Hypertension (HTN): Controlling BP < 140/90, age 18-85
- ACO 29 a/b (NQF 0075): Ischemic Vascular Disease, Lipid Profile Performed, age 18 & up, LDL Control < 100
- ACO 30 (NQF 0068): Ischemic Vascular Disease, Use of aspirin/ alternate Rx, age 18 & up.
- ACO 31 (NQF 0083): Heart Failure, EF < 40%, use of beta blocker
- ACO 32 (NQF 0074): CAD, drug therapy for lowering LDL
- ACO 33 (NQF 0066): CAD, ACE/ ARB use if also DM or LVEF < 40%



Key Strategies for Operations and Analytics

- Apply to all patients, not just at risk care patients
- "Proven performance" needed for new business strategies and steerage
- Strengthening of regional network to promote the health of patients across our state and region.
- Using Registry Analytics for patient attribution by:
 - Financial Class
 - Disease Registry
 - PCP
 - Demographics

Billings Clinic. ACO Dashboards & Data:

- 1. Un-blinded Monthly Dissemination of Data
 - Physician, Pod (Medical Home), Department, Location
 - Text, Email, Intranet
- 2. Process:
 - 1. Standing Agenda Item at Department Meetings (including compensation model)
 - 2. Analytics for physicians to drill down on data

ACO Report Card



Physician Report Card

re	1		Cumul	lative	(è	M	ay-13	2	A	pr-13		N	ar-13	18	Fe	b-13	5	1	Jan-
	Panel size:				J.,														T
nation/ Patient Safety Domain	Measure	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	P
Sized All Condition Readmission	ACO 8 NQF 1789				-				1000	# per month		0.000	# per month	9		# per month			T
ensitive Conditions Admissions: COPD/ or Asthma, age 40	ACO 9 NQF 0275									# per month			# per month			# per month			
ensitive Conditions Admissions: Heart Failure (HF), age 18	ACO 10 NQF 0277									# per month			# per month			# per month			
Physicians who Successfully Qualify for an EHR Program	ACO 11									Yes/ No			Yes/ No			Yes/ No			
econciliation following transition in care	ACO 12NQF 0097									% of eligible visit	\$		% of eligible vis	ts		% of eligible visi	ts		
Future Fall Risk, age 65 and up	ACO 13 NQF 0101									N/A			% of eligible vis	ts		% of eligible visi	ts		
e Care Domain	Measure	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	P
nunization, age 6 mp and up	ACO 14NQF 0041	20647	24120	36%	3845	4846	9%	3488	4341	80%	4322	4835	89%	4409	4780	92%	4583	5318	8
Il Vaccination for Patients 65 Years and Older	ACO 15 NQF 0043	8291	9454	3 88%	1766	2021	87%	1562	1760	3 89%	1663	1918	87%	1607	1821	38%	1693	1934	40
dex (BMI) Screening, age 18 and up, calculated Q.6 mo	ACO 16aNOF 0421	20353	22872	3 89%	4293	4604	93%	3797	4098	93%	4249	4605	92%	4189	4532	92%	3825	5033	13
idex (8MI) Follow-Up Plan Documented	ACO 16b NOF 0421	707	15807	3 4%	184	3406	5%	175	2960	656	129	3330	3 4%	131	3295	O 4%	88	2816	10
Screening, age 18 & up	ACO 17aNQF 0028	21503	22872	94%	4426	4604	96%	3918	4098	96%	4394	4605	95%	4264	4532	94%	4501	5033	3 9
Cessation Intervention, age 18 & up	ACO 17b NQF 0028	545	2980	3 18%	112	564	20%	88	521	IT%	100	587	3 17%	122	616	20%	123	692	13
Clinical Depression, age 12 & up	ACO 18aNOF 0418		1000	N/A			N/A			N/A			N/A			N/A	1.1.1		N
Clinical Depression Follow-Up Plan, age 12 & up	ACO 18bNOF 0418			N/A			N/A			N/A			N/A			N/A			N
incer Screening, age 50-75, iFOBT 1 yr, colonoscopy 10 yr	ACO 19NQF 0034	7947	11995	66%	1598	2508	64%	1415	2134	66%	1633	2445	67%	1652	2468	67%	1649	2440	0
r Screening, age 40-69, with mammogram in 24 months	ACO 20NQF 0031	5391	7202	3 75%	1142	1489	3 77%	942	1265	3 74%	1134	1522	3 75%	1158	1530	3 76%	1015	1396	5 🖸
high blood pressure (age 18 and up)	ACO 21a	22246	22872	97%	4571	4604	99%	4061	4098	99%	4570	4605	99%	4491	4532	99%	4553	5033	10
in for high blood pressure documented (age 18 and up)	ACO 21b			N/A	ine o		N/A			N/A		1.00	N/A	10000	Contraction of the	N/A			N
alation Domain: Disease Management	Measure	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	Performance*	Num	Den	P
litus: HgA1c Control (< 8%), age 18-75	ACO 22NQF 0729	2773	3795	73%	589	784	75%	598	799	75%	534	726	74%	548	755	73%	504	731	0
litus: LDL Control < 100, age 18-75	ACO 23NQF 0729	1898	3795	50%	419	784	53%	403	799	50%	338	726	47%	376	755	S0%	362	731	0
litus: 8P Control < 140/90, age 18-75	ACO 24 NQF 0729	2855	3795	3 75%	617	784	2 79%	608	799	3 76%	539	726	3 74%	560	755	9 74%	531	731	3
litus: Tobacco Non-Use, age 18-75	ACO 25NQF 0729	3501	3795	92%	729	784	93%	749	799	94%	666	726	92%	685	755	91%	672	731	0
litus: Aspirin or Antiplatelet Rx for DM & IVD, age 18-75	ACO 26NQF 0729	600	1059	57%	151	281	54%	254	393	3 65%	67	135	50%	61	121	S0%	67	131	0
litus: HgA1c Poor Control, A1c > 9%, age 18-75	ACO 27NQF 0059	350	3795	9%	69	784	9%	71	799	9%	64	726	9%	65	755	9%	81	731	3
(HTN): Controlling BP < 140/90, age 18-85	ACO 28 NQF 0018	8339	11548	72%	1763	2332	54%	1734	2404	3 65%	1698	2329	3%	1569	2244	9 70%	1575	2239	0
cular Disease (IVD): Lipid Profile performed, age 18 & up	ACO 29a NQF 0075	2602	3025	36%	558	649	86%	547	635	86%	511	592	86%	491	572	86%	495	577	0
cular Disease (IVD): LDL Control < 100, age 18 & up	ACO 29bNQF 0075	1753	3025	58%	377	649	58%	362	635	57%	336	592	57%	342	572	60%	336	577	0
cular Disease (IVD), Use of aspirin/ alt Rx, age 18 & up	ACO 30 NQF 0058	1614	3025	53%	349	649	54%	348	635	55%	331	592	56%	287	572	50%	299	577	6
EE < 10H use of both blackes (are 18 and un)	ACO 31 NQF 0083	97	276	35%	16	52	31%	26	60	43%	18	57	32%	17	58	29%	20	49	0
, EF < 40%, use of beta blocker (age 18 and up)																			
rapy for lowering LDL (age 18 and up)	ACO 32 NOF 0074	2055	2698	76%	450	585	77%	417	553	75%	404	527	77%	388	514	75%	396	519	



Year to Date Performance

Physician Report

re			0	native	0-1	May-13			7	Apr-13			Mar-13		F	eb-13		Jan-	-11
	Panel size:																		
nation/ Patient Safety Domain	Measure	Num	Den	Performance*	Num	Den	mance*	Num	Den	Performance*	Num	Den	Performance	e* Num	Den	Performance*	* Num	Den P	Pe
fized All Condition Readmission	ACO 8 NQF 1789			N N						# per month			# per month			# per month			
ensitive Conditions Admissions: COPD/ or Asthma, age 40	ACO 9 NQF 0275			4						# per month			# per month			# per month			
ensitive Conditions Admissions: Heart Failure (HF), age 18	BACO 10 NQF 0277																		
Physicians who Successfully Qualify for an EHR Program	ACO 11					N				Pe			A K M	~ /	AV				
econciliation following transition in care	ACO 12NQF 0097																		
Future Fall Risk, age 65 and up	ACO 13 NQF 0101																		
e Care Domain	Measure	Num	Den																
nunization, age 6 mp and up	ACO 14NQF 0041	20647	24120																
Il Vaccination for Patients 65 Years and Older	ACO 15 NQF 0043	8291	9454							/ De			A X						
dex (BMI) Screening, age 18 and up, calculated Q.6 mo	ACO 16aNOF 0421	20353	22872								5				/0				
idex (BMI) Follow-Up Plan Documented	ACO 16b NOF 0421	707	15807	0		2000	576	Contrast 1		0		3330	<u> </u>				1 .00		1
Screening, age 18 & up	ACO 17aNQF 0028	21503	22872	94%	4426	4604 3	96%	3918	4098	3 969	4394	4 4605	95	5% 4264	4 4532	94%	4501	5033	
Cessation Intervention, age 18 & up	ACO 17b NQF 0028	545	2980	O 18%	112	564 🥥	20%	88	521	O 17%	100	587	3 17	7% 122	616	20%	123	692 🙆	
Clinical Depression, age 12 & up	ACO 18aNQF 0418			N/A		N/A				N/A			N/A			N/A		N	A/A
Clinical Depression Follow-Up Plan, age 12 & up	ACO 185NOF 0418			N/A		N/A				N/A			N/A			N/A		N	ALA
incer Screening, age 50-7												3 2445		7% 1652	2 2468	140.10	6 1649	2440	
r Screening, age 40-69,	MADOR										and the second second	4 1522			8 1530			1396 🤤	
high blood pressure (a	lyperl									995	4570	0 4605	99	9% 4491	1 4532	99%	4553	5033	
in for high blood press													N/A			V N		N	4/4
alation Domain: Dise										ance*	-	n Den	Pel prmance	e* Num	n Den	and the second se	-	Den F	Pe
litus: HgA1c Control (<)										75%	6 534	721	3 75	4% 548		73%	6 504	731	
litus: LDL Control < 100	pecific	~ 27		Ang		Sh	AC			50%	% 338	72	Q 47	7% 376		50%	6 362	731 🔾	
litus: BP Control < 140/		<u> </u>								76%	\$ 539	72	9 74	5 5		All suggestion of the local division of the			
litus: Tobacco Non-Use, age 18-75		3501	3/95	92%	129	784	93%	749	799	94%	6 666	7	92	55					
litus: Aspirin or Antiplatelet Rx for DM & IVD, age 18-A	19	600	1059	57%	151		54%	254	393	65%	6 67	2	3 5						
litus: HgA1c Poor Control, A1c > 9%, age 18-75	QF 0059	350	3795	9%	69	784	9%	71	799	9%	6 64	7 5	0			or Sy	m	201	
(HTN): Controlling BP < 140/90, age 18-85	NQF 0018	8 8339	11548	72%	1763	2332	54%	1734	2404	3 659	1698	8 2 9	0						4
cular Disease (IVD): Lipid Profile performed, age 18 & up	AC NQF 0075	2602	3025	36%	558	649 3	86%	547	635	86%	6 511	5 2	0						
cular Disease (IVD): LDL Control < 100, age 18 & up	ACO 29bNQF 0075	5 1753	3025	58%	377	649 🔾	58%	362	635	57%	\$ 336	SE		ATC.	r	Bench	m	ar	٨ç
cular Disease (IVD), Use of aspirin/ alt Rx, age 18 & up	ACO 30 NQF 0058	8 1614	3025	53%	349	649 3	54%	348	635	55%	6 331	5	0 5						4
EF < 40%, use of beta blocker (age 18 and up)	ACO 31 NQF 0083	3 97	276	35%	16	52 3	31%	26	60	43%	18	3	37						
rapy for lowering LDL (age 18 and up)	ACO 32 NQF 0074	2055	2698	76%	450	585 🥥	77%	417	553	75%	6 404	52	0 77	7% 3.					
			1201	72%	A DESCRIPTION OF	COLUMN DATE		4	A COLUMN TO A	3 75%	A DESCRIPTION OF		3 75			70%	6 157	222	

Timely Frontline Information

- As or more important than compensation strategies
- Real promise in this arena over the next 2-5 years

Analytics / Decision Support



Clinical, Financial & Operational Data

人



Billings Clinic MD Compensation Goals

- Desired Features of Compensation System
 - Supports organization's mission, vision & values
 - Considers constraints & maximizes flexibility of current systems
 - Competitive based on comparable "market" analysis
 - Perceived as equitable by physicians
 - Represents sound business principles
- Philosophy
 - Achieves alignment & consistency within Billings Clinic
 - Facilitates group concept within Billings Clinic
 - Incentivizes individual productivity & enhances individual satisfaction
 - Provides incentives for achievement of Clinic goals
 - Avoid inappropriate incentives
 - For ex booking credit for ancillaries ordered
 - Ownership incenting unnecessary volume
- Architecture
 - Is understandable & uniform in administration
 - Provides fair & accurate measurement across all revenue lines
 - Enhances the ability to recruit & retain physicians in the market
 - Aligns with organizational objectives and is affordable
 - Regulatory Requirements
 - Improves the competitive strength of the system

MD Compensation Evolution

- "Eat what you kill"
- % Net Bookings
- RVUs and conversion factors
- % individual production vs =share in group practices
- How to benchmark MD nonRVU work
- Increasing MD diversity
- Approaches to market total compensation

Billings Clinic MD Compensation

- 100 % RVU/conversion factor productivity
- 100 % RVU cf productivity plus QSL (5-10%)
- Straight salary
- Straight salary plus QSL (5-10%)
- Equal weight productivity/value metrics

Primary Care Compensation Strategy

- Value Based Movement
 - Focus from production to value based care
 - Primary Care compensation model is a blended model
 - Salary model based on median salary adjust for four components of performance
 - 10% Based on Team Production (Location based)
 - 40% Based on Individual Production (MD only)
 - 25% Based on Individual Quality Measures
 - 25% Based on Team and Individual Access Measures
 - Four components are based on three tiers
 - Minimum (25% lower than AMGA median compensation)
 - Median
 - Maximum (25% higher than AMGA median compensation)
 - Model design in 2012; transition year was 2013 when the blended method was modeled for Primary Care with the first impact to their salaries happening in 2014

Internal Medicine Compensation

Primary Care Example		Survey median		nus 25% inimum)		lus 25% aximum)
1.0 FTE		\$ 250,000	\$	187,500	\$	312,500
Component	Weight	Median	М	inimum	Ma	aximum
Quality	25%	\$ 62,500	\$	46,875	\$	78,125
Access	25%	\$ 62,500	\$	46,875	\$	78,125
Team Production	10%	\$ 25,000	\$	18,750	\$	31,250
Individual Production	40%	\$ 100,000	\$	75,000	\$ 1	125,000

Production Scorecard – Produced Monthly (AMGA 2012)

Access	Frequency	Meas Target	Target Source	Min	Med	Max
Team Production*	Monthly	% of AMGA Median	AMGA	0-84%	85-114%	115%+
Individual Production*	Monthly	% of AMGA Median	AMGA	0-84%	85-114%	115%+
* FTE Adjusted Measure						

Provider	Team	Clinical FTE	Actual OP RVU's	FTE Adj RVU's	AMGA Median	% Median
IM Phys 1	Delta	0.8	4,600	5,750	4,717	122%
FM Phys 1	Delta	1.0	4,700	4,700	4,890	96%
Primay PA	Delta	0.9	3,500	3,889	3,665	106%
Primary NP	Delta	1.0	3,400	3,400	3,315	103%
Team Total		3.7	16,200	17,739	16,587	107%

Access Score Card

	Spec Code	1210	Team FTE	6.41				
	Team	IMR Faculty		Amb FTE	1.00	Pay FTE	1.00	
Scoring Measures								
Quarter	Q4	Q4	Q4	Calendar	Calendar	Calendar		Comp
Calendar Year	2014	2014	2014	2014	2014	2014	% of	
Month	Oct	Nov	Dec	YTD	YTD FTE Adj	Target	Target	Score
Billed ambulatory visits - AMGA Definition	73	195	184	2,134	2,134	3,356	63.6%	1
HCC Score 2014 Standards (Age > 18 Only)	0.755	0.755	0.755	0.755	N/A	0.669	112.9%	2
Team Panel AMGA weighted (Quarterly)	10,309	10,309	10,309	10,309	11,275	12,192	92.5%	2
% Same Day Appointments Physician	11.6%	11.7%	12.2%	8.5%	N/A	6.5%	130.4%	3
% Same day appts team	19.8%	17.4%	17.8%	18.3%	N/A	10.0%	183.4%	3
								11
Provider is part of Team Roll Up	Y							
Scoring								
< 85% of Target =	1							
>= 85% of Target - < 115% of Target =	2							
>= 115% of Target =	3							

Panel Reporting 2015 (Healthy Registry)

HealtheRegistries	Registries	Scorecards					<mark>م</mark>	Hepp, Craig E
Scorecards	<						Score	ecard Details 🔹
Organizations Green Providers Q Search Providers	Internal Medicin 981 Scorable 1,026 Person	Persons	Composite Score 76.92 [%]	•				
LE Sort By: Composite Score	★ Тор Ор	portunities	Il categories 💌 All programs 💌 %	of Target 💌				
	Measure			% of Target	Met %	Completion %	Numerator	Denominator
	Diabetes M	ellitus : Tobacco I	Non-Use	67 [%]	57%	64 [%]	77	134
Internal Medicine	Preventive	Care : Screening	for High Blood Pressure and Follow-Up	72 [%]	57%	91 [%]	239	413
	Influenza In	nmunization : Influ	enza Immunization - Full Season	80 [%]	70%	70%	626	889
	Preventive	Care : Body Mass	Index Screening and Follow-Up	81 [%]	65 [%]	74%	635	968
	Preventive	Care : Colorectal	Cancer Screening	96 [%]	77%	77%	442	573
	Preventive	Care : Tobacco U	se Screening and Cessation Intervention	98%	79 [%]	79 [%]	769	972
Internal Medicine	Diabetes M	ellitus : HbA1c Po	or Control	100 [%]	14 [%]	100 [%]	20	134
	Metrics With	n All Targets Met						View Persons

35

Process

•The Physician Compensation Committee (PCC) is integral in the compensation plan for the organization

- The PCC oversight of physician compensation in the organization.
 Membership is a combination of senior leadership, physicians and compensation analysts
- Committee role
 - Review staff physician compensation and production and compare to annual market data. The Committee makes recommendation to Leadership Council (LC)
 - Identify issues and alternatives for pay plan design, standard pay practices and policies
 - Discuss all special requests and make recommendation to LC

Department recommendations

- Department Chair and Leadership may bring recommended department compensation model for review by the PCC
 - Intensivist compensation model
 - Primary Care

Lessons Learned

- Core principles for all compensation plans important
- One compensation model does not meet the needs for variability between departments
- When incorporating quality metrics the EHR should be robust to provide electronic collection of data for providers



MARKET EVALUATION MATRIX 2014

	FY14 Billings Clinic Data	AMGA 2014	Comparison
1	Wrvu %tile	50th %tile (median)	At or above
2	Effective CF: Total compensation / wrvu (survey definition)	Comp to work ratio	Within 10%?
3	Wrvu FY14 Wrvu X CY14 CF +other comp	Wrvu %tile	Alignment & "Gap" within 10%tile points
4	Wrvu, total compensation	Scatter gram	(if producing > median) at or above best fit & within 1 std deviation
5	Other items for discussion:	Recruitment Retention	Other Department specific issues

MD Compensation and Value

- "Market" competiveness remains critical
- Underlying RVU and CF process determinations critical and controversial
- Uneven FFS payment issues (including hospital) at play as well and influential
- Recognizing work outside of patient visits
- Retail, Televisits, Outreach, Remote Consultation

Value Based Payment: Thoughts

- Current MSSP and Bundling designs complex and imperfect
- Data and real time information issues
- Beneficiary attribution and engagement
- Risk/benefit balance
- Low volume and low cost markets
- Socioeconomic and demographic variation
- Immature Electronic Health Information Systems
- Cost

MD Compensation and Health Reform

- Culture and values remain important
- Value can be delivered in most payment systems- importance of collegiality and investment in teams, timely information, patient centered focus, partnerships across the continuum
- Non-financial incentives critical

Non Financial Incentives

- Resources: Team including NP, PA, LPN, MA, RN navigators, Pharmacists, Social Workers
- EHR w real time feed back and analytics (this remains a mixed bag for MDs but is slowly improving)
- Sense of better results for patients than historical time-limited intermittent patient visit

Questions

- Nicholas Wolter, MD
- 406-238-2609
- nwolter@billingsclinic.org